Industry analysts and academic specialists identify automation, AI‑driven process control, and trained biomanufacturing staff as the most effective levers to relieve CAR‑T production constraints. Reports emphasize decentralization, closed automated systems, and in‑process analytics to shorten vein‑to‑vein times and reduce reliance on expensive cleanrooms. Sartorius responded with the Eveo Cell Therapy Platform, a modular, semi‑automated system that integrates selection, activation, gene modification and QC in a closed format designed to increase throughput and enable parallel processing of autologous patient batches. Pilot data from partners indicate the platform can compress manufacturing footprints and operator needs, signaling industrial moves to embed automation into cell‑therapy supply chains.